Oct 9, 2019   SOURCE: PR NewsWire

Pipeline Review on Hidradenitis Suppurativa Pipeline Review - H2 2019

DUBLIN, Oct. 9, 2019 /PRNewswire/ -- The "Hidradenitis Suppurativa - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2019, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 3, 5 and 5 respectively.

Scope

    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Hidradenitis Suppurativa (Dermatology).
    --  The pipeline guide reviews pipeline therapeutics for Hidradenitis
        Suppurativa (Dermatology) by companies and universities/research
        institutes based on information derived from company and
        industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
        stages.
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Hidradenitis
        Suppurativa (Dermatology) therapeutics and enlists all their major and
        minor projects.
    --  The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology)
        therapeutics based on mechanism of action (MoA), drug target, route of
        administration (RoA) and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Hidradenitis Suppurativa (Dermatology)

Reasons to buy

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Hidradenitis Suppurativa (Dermatology).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
        companies.
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of
        Indication therapeutics.
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered: 

    --  Introduction
    --  Report Coverage
    --  Hidradenitis Suppurativa - Overview
    --  Hidradenitis Suppurativa - Therapeutics Development
    --  Pipeline Overview
    --  Pipeline by Companies
    --  Products under Development by Companies
    --  Hidradenitis Suppurativa - Therapeutics Assessment
    --  Assessment by Target
    --  Assessment by Mechanism of Action
    --  Assessment by Route of Administration
    --  Assessment by Molecule Type
    --  Hidradenitis Suppurativa - Companies Involved in Therapeutics
        Development
    --  AbbVie Inc
    --  Aclaris Therapeutics Inc
    --  Alvotech ehf
    --  AstraZeneca Plc
    --  Celgene Corp
    --  ChemoCentryx Inc
    --  CSL Ltd
    --  Foamix Pharmaceuticals Ltd
    --  Glenmark Pharmaceuticals Ltd
    --  Immunwork Inc
    --  Incyte Corp
    --  InflaRx NV
    --  Innovation Pharmaceuticals Inc
    --  InSight Biopharmaceuticals Ltd
    --  Johnson & Johnson
    --  Novartis AG
    --  UCB SA
    --  XBiotech Inc
    --  Hidradenitis Suppurativa - Drug Profiles
    --  ABBV-3373 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  adalimumab biosimilar - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  adalimumab biosimilar - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  adalimumab biosimilar - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  adalimumab biosimilar - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  adalimumab biosimilar - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  apremilast - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  ATI-450 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  avacopan - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  bermekimab - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  bimekizumab - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  brilacidin - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  brodalumab - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  CJM-112 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  CSL-324 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  doxycycline hyclate - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  GBR-830 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  guselkumab - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  IFX-1 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  INCB-54707 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  iscalimab - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  LYS-006 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  risankizumab - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  secukinumab - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  TE-2232 - Drug Profile
    --  Product Description
    --  Mechanism Of Action
    --  R&D Progress
    --  Hidradenitis Suppurativa - Dormant Projects
    --  Hidradenitis Suppurativa - Discontinued Products
    --  Hidradenitis Suppurativa - Product Development Milestones
    --  Featured News & Press Releases
    --  Appendix
    --  Methodology
    --  Coverage
    --  Secondary Research
    --  Primary Research
    --  Expert Panel Validation
    --  Contact Us
    --  Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/k877yp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/pipeline-review-on-hidradenitis-suppurativa-pipeline-review---h2-2019-300934625.html

SOURCE Research and Markets